AM-Pharma BV, an emerging leader specializing in the development of treatments for serious diseases, today announced that Lars Boesgaard, Chief Financial Officer, is to present at the Jefferies Healthcare Conference, to be held in New York on Wednesday, June 8, 2022 at 8:00 a.m. (Eastern Time).

About AM-Pharma

AM-Pharma's goal is to save and improve the lives of patients facing serious illnesses. Our initial focus is acute kidney injury associated with sepsis, which is the cause of death for hundreds of thousands of people hospitalized every year. Our proprietary compound, ilofotase alfa, has the potential to become the first treatment for sepsis-associated acute kidney injury and is currently in a pivotal Phase III global clinical trial. We are a dedicated team striving to bring treatment options to critically ill patients, their families and acute care professionals. To learn more about us, visit our website: www.am-pharma.com .

The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared with the source text, which will set a precedent.

Contacts
Investors:
Argot Partners
+1 212.600.1902
AMPharma@argotpartners.com

Media:
Trophic Communications
Gretchen Schweitzer
+49.89.238.877.30
Am-pharma@trophic.eu

 

Source:businesswire.com

Report Abuse